论文部分内容阅读
目的：观察药物治疗慢性鼻-鼻窦炎（CRS）疗效。方法选择2012年1月至2015年1月沈阳军区总医院收治的12周岁以上，根据症状、鼻内镜检查及CT表现确诊为不伴鼻息肉的CRS患者150例，口服克拉霉素缓释片、盐酸氨溴索片（沐舒坦）和鼻渊通窍颗粒3种药物，糠酸莫米松鼻喷雾剂喷鼻。治疗4～6周复查，若患者主观症状缓解或消失，CT提示CRS消失，将克拉霉素减半继续服用至12周，停用其他药物。若仅有主观症状改善，CT显示仍有CRS存在，则继续合并用药，最长用药12周，治疗后4周，根据治疗前后症状及CT表现，分别采用视觉模拟量表（VAS）和Lund-Mackey鼻窦CT扫描病变范围评分系统对临床疗效进行主观与客观评估。结果150例CRS患者治疗前VAS得分为（7.65±1.63）分，治疗后为（2.12±1.18）分，治疗前后得分比较差异有统计学意义（t=28.13，P<0.01）。Lund-Mackey鼻窦CT量化评估：治疗前（8.27±1.46）分，治疗后为（2.34±1.58）分，治疗前后得分比较差异有统计学意义（t=27.35， P<0.01）。按左右两侧（共259侧）进行Lund-Mackey鼻窦CT量化评估，治疗前后炎症变化的构成比较，治疗前中度以上炎症比率高达78.76%，治疗后仅为9.27%，差异有统计学意义（χ2=184.98， P<0.01）。结论沐舒坦联合克拉霉素缓释片及鼻渊通窍颗粒对CRS疗效明显，12岁以上不伴鼻息肉CRS应首选药物治疗。“,”Objective To observe the effect in the treatment of chronic rhinosinusitis(CRS) with drug therapy. Methods More than 12 years old patients,based on the symptoms,endoscopic and CT shows,150(259 sides) cases with chronic rhinosinusitis without nasal polyp were studied with the drugs of macrolideantibiotics (Clarithromycin sustained release tablets ),mucolytic agent (Mucosolvan),ready made patent drugs(Biyuan tongqiao particles) and steroid nasal spray,and reviewed after 4~6 weeks of the drug therapy.If the patients felt and CT showed very well,the drugs were stoped except clarithromycin,but only half dose of clarithromycin was remained using up to 12 weeks.If not,all the drug would be continued and whether be regulated or continued depending on the show of symptoms and CT .the longest time of therapy was 12 weeks.Finaly,the therapeutic effect was evaluated using methods of Visual analogue scale(VAS) and Lund-Mackey after 4 weeks of stoping drugs. Results The scores of VAS were respectively (7.65±1.63) and (2.12±1.18),and the scores of Lund-Mackey were respectively(8.27±1.46) and (2.34±1.58) before and after therapy,there were significant difference in the evaluation of VAS (t=28.13,P<0.01) and Lund-Mackey (t=27.35,P<0.01)between before and after therapy.At the change of proportion of 259 sides of both left and right with CRS on the evaluation of analysis of side accounts using Lund-Mackey, CRS over middle degree accounted for 78.76%before therapy,but it only was 9.27%after therapy. There was also significant difference(χ2=184.98,P<0.01). Conclusion Mucosolvan combined with Clarithromycin sustained release tablets and Biyuan tongqiao particles has a significant and stable effect for CRS without nasal polyps, it should be the first choice for the patients of more than 12 years old .